Abbott Laboratories beat fiscal second-quarter 2026 estimates and raised its full-year adjusted earnings guidance, while Danaher Corporation cut its core revenue growth outlook following mixed quarterly results. Abbott reported adjusted diluted EPS of $1.31, with diagnostics sales surging 42% to $3.09 billion, and lifted its 2026 adjusted EPS forecast to a range of $5.45 to $5.60. Danaher posted a 5.5% revenue increase to $6.3 billion and adjusted EPS of $1.94 that exceeded analyst estimates, but lowered the upper end of its full-year core revenue growth outlook to 4% from 6%, citing weaker respiratory testing revenue. Hedge fund ownership of Abbott rose to 73 in the first quarter of 2026, while Danaher's fell to 110, reflecting diverging institutional sentiment.
Abbott LaboratoriesBeat Q2 estimates and raised full-year adjusted EPS guidance.
Danaher CorporationCut full-year core revenue growth outlook to 4% from 6%.